Nipruss (Sodium Nitroprusside Dihydrate)

Sodium nitroprusside releases nitric oxide when it enters the bloodstream. The nitric oxide activates guanylate cyclase, increasing cyclic GMP levels in vascular smooth muscle. Elevated cyclic GMP causes smooth‑muscle relaxation, leading to dilation of arteries and veins, which reduces both preload and afterload and rapidly lowers systemic blood pressure.

The dosing of Nipruss is individualized and must be determined by the prescribing clinician. Typically, the infusion is started at a low rate and titrated based on continuous blood pressure monitoring to achieve the desired therapeutic effect while avoiding excessive hypotension.

Safety data for sodium nitroprusside in pregnancy and lactation are limited. It should be used only if the potential maternal benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with obstetric specialists.

To order Nipruss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with agents such as nitroglycerin or nicardipine, sodium nitroprusside offers a more rapid onset and a balanced arterial‑venous dilation, allowing precise control of both preload and afterload. However, it requires vigilant monitoring for cyanide toxicity, a concern less prominent with many alternative IV antihypertensives.

Nipruss should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion should be discarded according to local regulations after the recommended shelf‑life.

Nipruss is given as an intravenous infusion. The solution is diluted in a compatible carrier (often normal saline) and administered through a calibrated infusion pump. Continuous arterial blood pressure monitoring is essential, and the infusion rate is adjusted by the clinician to achieve the target hemodynamic response.

The most critical risks include cyanide toxicity, which can manifest as metabolic acidosis, altered mental status, or seizures, and severe hypotension leading to organ hypoperfusion. Prompt recognition, regular laboratory monitoring, and availability of cyanide antidotes are vital to mitigate these hazards.

Nipruss is contraindicated in patients with known hypersensitivity to sodium nitroprusside or its excipients, those with severe anemia, vitamin B12 deficiency, or significant renal or hepatic impairment that could impair cyanide clearance. It should also be avoided in patients with uncontrolled sepsis or shock where rapid vasodilation could worsen perfusion.